| treatment |
|
comparator |
|
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Yang, 2015 | | | |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs dlipizide add on metformin | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Nauck, 2011 | Dapagliflozin in Combination With Metformin | Sulphonylurea in Combination With Metformin | Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Therapy Alone |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Ferrannini (MB102013), 2010 | a morning dose of 5 or 10 mg/day dapagliflozin | placebo | treatment-naive patients with type 2 diabetes | | Komoroski (MB102007), 2009 | daily oral doses of 5-, 25-, or 100-mg doses of dapagliflozin | placebo | patients with type 2 diabetes mellitus | | List (MB102008), 2009 | one of five dapagliflozin doses | placebo | type 2 diabetic patients | | KOhan, 0 | Dapagliflozin monotherapy | placebo | | | Kohan, 0 | Dapagliflozin | placebo | Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Contro | | Kohan, | Dapagliflozin as Monotherapy | placebo | Japanese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | | Kaku, 2014 | | | |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo (add on insulin) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Wilding (MB102009), 2009 | 10 mg dapagliflozin, or 20 mg dapagliflozin, plus OAD(s) and 50% of their daily insulin dose | placebo | patients with type 2 diabetes that is poorly controlled with high insulin doses plus oral antidiabetic agents | | Wilding, 2012 | Dapagliflozin | placebo on top of insulin | Type 2 Diabetes With Inadequate Glycaemic Control on Insulin |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo (add on MET + SAXA) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Mathieu, 2015 | | | |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo (add on MET) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Bailey (MB102014), 2010 | dapagliflozin (2¡¤5 mg, n=137; 5 mg, n=137; or 10 mg, n=135) | placebo | adults with type 2 diabetes who were receiving daily metformin (¡Ý1500 mg per day) and had inadequate glycaemic control | | Bolinder, 2012 | dapagliflozin | placebo or Sitagliptin (on top MET) | | | Schumm-Draeger , 2015 | Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD | placebo | Patients With Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo (add on MET+SU) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Matthaei, 2015 | | | |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo (add on TZD) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Rosenstock, 2012 | Dapagliflozin in Combination With Thiazolidinedione | Thiazolidinedione | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo (on top standard treatment) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| MB102035, | Dapagliflozin
Tablets, Oral, 10 mg, once daily, 12 weeks | placebo | | | Cefalu, 2015 | Dapagliflozin
10 mg tablet, oral, once daily, 24- week | placebo | | | Leiter, 2016 | Dapagliflozin
10 mg tablet, oral, once daily, 24- week treatment | placebo | Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care | | MB102073, | Dapagliflozin
Tablets, Oral, 10 mg, once daily, up to 12 weeks | placebo | patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin Receptor Blocker (ARB). | | Weber, | Dapagliflozin
Tablets, Oral, 10 mg, once daily, Up to 12 weeks | placebo | Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs placebo add on DPP-4 | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| MB102061, | Dapagliflozin
10 mg tablet, oral, once daily, 48 weeks | placebo | Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a DPP-4 Inhibitor Sitagliptin+/-Metformin |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs Saxagliptin (add on MET) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Rosenstock, 2015 | | | |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs dapagliflozin | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Kohan, 0 | Dapagliflozin in Combination With Metformin | Dapagliflozin Monotherapy | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs glimepiride | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Strojek, 2011 | Dapagliflozin in Comb.With Glimepiride | glimepiride alone | Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone |
|
| Dapagliflozin | diabetes type 2, in all type of patients | vs metformin or dapa | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| MB102034, 2016 | Dapagliflozin 10 mg in Combination With Metformin | Dapagliflozin 10 mg Monotherapy or Metformin Monotherapy | Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Kadowaki, 2013 | | | Japanese patients with type 2 diabetes | | Kadowaki , 2014 | | | |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs Glimepiride + MET | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Ridderstrale, 2014 | BI 10773 dose plus metformin | Glimepiride 1-4 mg plus metformin | |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs linagliptin (add-on MET) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| DeFronzo, 2015 | | add-on to metformin for 52 weeks | subjects with type 2 diabetes inadequately controlled on metformin |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs linagliptin (monotherapy) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Lewin, 2015 | empagliflozin 25 mg/linagliptin 5 mg (n = 137), empagliflozin 10 mg/linagliptin 5 mg (n = 136), empagliflozin 25 mg (n = 135), empagliflozin 10 mg (n = 134) | linagliptin 5 mg (n = 135) for 52 weeks |
|
|
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EMPA-REG OUTCOME, 0 | | | | | Barnett, 2014 | / BI 10773 low dose (BI 10773 tablets once daily)
2/ BI 10773 high dose (BI 10773 tablets once daily)
| Placebo | Patients With Mild or Moderate Renal Impairment | | Ferrannini, 2013 | empagliflozin 5, 10 or 25 mg once daily | placebo | | | EMPA-REG MONO (Roden) vs placebo, 2013 | | | | | Kadowaki, 2015 | empagliflozin (5, 10, 25, or 50 mg) | placebo | Japanese patients with type 2 diabetes |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo (add on MET+/-PIO) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| EMPA-REG PIO (Kovacs), 2013 | once daily empagliflozin 10 mg (n = 165), empagliflozin 25 mg | add-on to pioglitazone ± metformin | |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo (add-on INS) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Rosenstock DOUBLON ???, 2013 | | | |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo (add-on INS+/-MET) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Rosenstock (1245.49), 2014 | once-daily empagliflozin 10 mg (n = 186), empagliflozin 25 mg (n = 189), | placebo | Patients inadequately controlled on MDI insulin ± metformin |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo (add-on MET) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Rosenstock, 2013 | | ??? | | | Ross, 2015 | empagliflozin 12.5 mg twice daily (n = 219), 25 mg once daily (n = 218), 5 mg twice daily (n = 219) or 10 mg once daily (n = 220), | placebo | patients with type 2 diabetes inadequately controlled on metformin | | EMPA-REG MET (Haring), 2014 | empagliflozin 10 mg (n = 217), empagliflozin 25 mg (n = 213), | placebo | Patients with HbA1c levels of ¡Ý7% to ¡Ü 10% (¡Ý53 to ¡Ü86 mmol/mol) while receiving metformin (¡Ý1,500 mg/day) |
|
| Empagliflozin | diabetes type 2, in all type of patients | vs placebo (add-on standard treatment) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Araki, 2015 | BI 10773 low dose (BI 10773 low dose tablet once daily)
2/ BI 10773 high dose (BI 10773 high dose tablet once daily)
| Metformin (Metformin tablets 500-2250 mg a day (twice or three times per day)) | Japanese patients with type 2 diabetes mellitus |
|
